MAP.AX ASX
Microba Life Sciences Limited
1W: -3.9%
1M: -10.9%
3M: +28.9%
YTD: -46.7%
1Y: -42.4%
3Y: -85.2%
A$0.05 ($0.03)
-0.00 (-2.04%)
Weekly Expected Move ±6.8%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$15M
-5.8% ▼
5Y CAGR: +31.6%
Gross Profit
-$12M
-257.8% ▼
Operating Income
-$20M
+17.5% ▲
Net Income
-$21M
-38.7% ▼
EPS (Diluted)
$-0.03
-3.6% ▼
EBITDA
-$16M
-51.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $5M | $5M | $12M | $16M | $15M |
| YoY Growth | +25.6% | +15.6% | +123.1% | +29.6% | -5.8% |
| Cost of Revenue | $2M | $12M | $6M | $8M | $26M |
| Gross Profit | $2M | -$7M | $6M | $7M | -$12M |
| Gross Margin | 50.5% | -125.0% | 48.8% | 47.5% | -79.5% |
| R&D Expenses | $5M | $9M | $11M | $2M | $417K |
| SG&A Expenses | $3M | $4M | $13M | $18M | $8M |
| Operating Expenses | $9M | $13M | $33M | $32M | $9M |
| Operating Income | -$16M | -$20M | -$27M | -$25M | -$20M |
| Operating Margin | -347.1% | -373.2% | -222.0% | -157.1% | -137.6% |
| Interest Expense | $55K | $60K | $69K | $177K | $239K |
| Income Before Tax | -$11M | -$19M | -$20M | -$15M | -$22M |
| Tax Expense | $9K | -$6M | -$51K | -$107K | -$1M |
| Net Income | -$11M | -$13M | -$20M | -$15M | -$21M |
| Net Margin | -244.6% | -233.9% | -164.9% | -95.3% | -140.4% |
| EPS (Diluted) | $-0.04 | $-0.04 | $-0.05 | $-0.03 | $-0.03 |
| EBITDA | -$10M | -$17M | -$17M | -$11M | -$16M |
| Shares Outstanding | 291M | 333M | 410M | 448M | 601M |